What Genoks does

Genoks Sağlık AŞ (operating as Genoks Genetik Hastalıklar Değerlendirme Merkezi) is a Turkish clinical genetic diagnostics laboratory headquartered in Ankara, founded in 2008 by Özden Bostan and licensed by the Turkish Ministry of Health (GHDM-SM/06.15/01). The company provides a comprehensive portfolio of genetic testing services spanning non-invasive prenatal testing (RapidNIPT), carrier screening (Genoks TATA Mini/Maxi/Maxi+SMA), whole exome sequencing (GenoXome), whole genome sequencing (GenoMESeq), and oncology genetics through its Onkogenoks sub-brand (GenoXonco-Plus comprehensive genomic profiling, GenoxLiquid liquid biopsy, HRD testing, and the GenoXhere hereditary cancer panel family). Testing is performed in a centralized laboratory in Ankara using multi-platform NGS technology including Illumina NextSeq and NovaSeq, MGI DNBSEQ-T7, BGI systems, and Twist Biosciences hybrid capture chemistry, with proprietary bioinformatics pipelines for variant calling, annotation, and clinical interpretation.

The company's business model is a centralized clinical laboratory services model. Samples are collected at partner hospitals and physician offices and shipped to the Ankara laboratory for analysis, with results returned through a proprietary LIMS portal (lims.genoks.com.tr). Revenue is generated primarily through test fees paid by healthcare providers, insurance reimbursement, or direct patient billing, depending on the structure of the relevant healthcare system. Genoks distributes its services through a B2B network of approximately 1,000 hospitals and 8,000 physicians across 15 countries, supplemented by direct-to-patient channels (online sample registration, results portal, and phone/WhatsApp hotline) and a health tourism offering targeting international patients. The company also offers complementary services including pharmacogenetics, prenatal chromosome analysis, and confirmatory testing using Sanger, MLPA, and FISH methods.

The customer base spans four primary segments: pregnant women and couples planning pregnancy seeking prenatal and carrier screening; oncology patients and at-risk individuals requiring hereditary cancer panels, tumor genomic profiling, liquid biopsy, and HRD testing; patients with suspected rare or undiagnosed genetic diseases referred for whole exome or whole genome sequencing; and the healthcare providers (hospitals, genetics clinics, physicians) who order testing and interpret results. Cumulative testing volume is reported at approximately 250,000 NGS tests and 150,000 NIPT tests, supported by a 1 Petabyte genetic data repository. Genoks is privately held, founder-controlled, and has no disclosed external funding rounds or parent company relationships.

Name

Genoks

Legal name

Genoks Sağlık AŞ

Website

https://genoks.com.tr

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

51–100 employees

Short description

Genoks is a Turkish clinical genetic diagnostics laboratory in Ankara offering NIPT, carrier screening, WES/WGS, and oncology panels (Onkogenoks) through NGS platforms, serving 1,000 hospitals and 8,000 physicians across 15 countries with a centralized lab and LIMS portal.

Ownership category

akta.pro rank

Product category

Clinical Genetic Diagnostics

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

Keywords

• Clinical genetic testing
• Non-invasive prenatal testing
• Next-generation sequencing
• Oncogenetics diagnostics
• Carrier screening services

Headquarters

HQ city

Yenimahalle

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Clinical Genetic Testing Services: Genoks operates as a genetic diagnostic laboratory providing clinical genetic testing services to healthcare providers and patients. Tests are performed in their central laboratory in Ankara and results are reported to ordering physicians. Revenue is generated through test fees, with payment collected from healthcare providers, insurance, or direct patient billing depending on the healthcare system structure in Turkey.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Genoks operates a centralized clinical genetic testing laboratory in Ankara delivering Next-Generation Sequencing (NGS) based diagnostic services. Its core offerings span non-invasive prenatal testing (RapidNIPT), reproductive carrier screening (Genoks TATA), hereditary and somatic oncogenetics panels (Onkogenoks, GenoXhere, GenoXonco-Plus), liquid biopsy (GenoxLiquid), HRD testing, and whole exome/genome sequencing (GenoXome, GenoMESeq), serving hospitals, physicians, and patients primarily across Turkey and 15 partner countries.

Product overview

Genoks Genetik Hastalıklar Değerlendirme Merkezi (Genoks Genetic Disease Assessment Center) operates as a genetic diagnostic laboratory offering a comprehensive portfolio of genetic testing services. The core offerings include prenatal screening (RapidNIPT for non-invasive prenatal testing), carrier screening (Genoks TATA with Mini/Maxi/Maxi+SMA options), and exome/genome sequencing (GenoXome WES and GenoMESeq WGS). The Onkogenoks sub-brand provides oncology services including hereditary cancer panels (GenoXhere BRCA, breast/ovarian, prostate, colon, prime, and plus panels), comprehensive genomic profiling (GenoXonco-Plus with 638 DNA + 22 RNA genes), liquid biopsy (GenoxLiquid), and HRD testing. Supporting services include pharmacogenetics, confirmatory tests (Sanger, MLPA, FISH), and prenatal chromosome analysis. The company utilizes NGS technology platforms including Illumina and MGI/BGI systems, operates under Turkish Ministry of Health license (GHDM-SM/06.15/01), and serves hospitals and physicians across 15 countries.

Differentiator

Problem solved

Functional benefit

Brands

• RapidNIPT: Genoks' non-invasive prenatal testing brand using cfDNA analysis from maternal blood, based on Illumina technology.
• Onkogenoks
• GenoXome
• GenoMESeq
• Genoxome
• GenoxLiquid
• GenoXhere
• Genoks TATA

Products and services

• RapidNIPT Non-invasive prenatal testing (NIPT) service analyzing cell-free fetal DNA (cfDNA) from maternal blood for chromosomal aneuploidies including trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome), available from the 10th week of pregnancy for expectant mothers referred by obstetricians.
• Genoks TATA (Taşıyıcı Tarama Testi) Carrier screening test evaluating autosomal recessive and X-linked genetic disease carrier status, offered in Mini, Maxi, and Maxi+SMA panel options covering conditions such as SMA, cystic fibrosis, Fragile-X, and DMD for couples planning pregnancy.
• Periferik Kandan Kromozom Analizi (Peripheral Blood Karyotyping)

Quantifiable outcome

• NIPT provides >99% accuracy for detecting trisomy 21, 18, and 13
• +3 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature7 records

Partnerships

One partnership is on record.

• VelseracoreStrategic or Co-development Partner · 1 January 2025Genoks GDHM's strategic collaboration with Velsera to advance cancer diagnostics in Turkey, as part of broader industry developments in the cancer biomarkers market. This partnership aligns with the global market growth driven by rising cancer incidence and increased adoption of personalized medicine approaches.

Scale indicators6 records

Recent moves4 records

Expansion highlights5 records

Direct peers

• Centogene: Germany-headquartered rare-disease and multi-omics diagnostics lab. Operates a comparable integrated NGS menu (NIPT, WES/WGS, hereditary panels, biomarker testing) with a similar European/EMEA geographic posture.
• GeneDx: Specialised clinical genomics lab (formerly within BioReference) focused on rare-disease exome/genome and hereditary cancer panels—directly comparable to Genoks' GenoXome WES and GenoXhere hereditary cancer franchises.
• Sophia Genetics: Genomic and multimodal analysis platform for hospitals and reference labs, recently expanding into cancer and rare-disease interpretation. Comparable as a hospital-facing NGS interpretation/clinical-decision stack, particularly given the Velsera partnership at Genoks.
• Natera: US-based genetic testing company operating across reproductive health (NIPT, carrier screening) and oncology (Signatera ctDNA, HRD), sharing both Genoks' prenatal franchise and oncology pipeline posture with NGS-based assays.
• Blueprint Genetics: NGS panels for hereditary disease and rare disorders across cardiovascular, ophthalmology, oncology and reproductive health; comparable to GenoXhere hereditary cancer panels and carrier screening portfolio.
• DNA Diagnostics Center (DDC): Specialised genetic testing laboratory offering NIPT, carrier screening, and hereditary panels—closest peer in product mix to Genoks' RapidNIPT, Genoks TATA and GenoXhere panels.

Broad incumbents

• Myriad Genetics: Long-established US molecular diagnostics leader with hereditary cancer (BRACAnalysis), prenatal, and oncology products—a broad incumbent whose oncology and reproductive menu overlaps Genoks' Onkogenoks and RapidNIPT franchises.
• Labcorp (Invitae): Global clinical laboratory and diagnostics giant with a major genetic testing business following the acquisition of Invitae; broad incumbent that competes with Genoks on NIPT, hereditary cancer, and oncology profiling at scale.
• Eurofins Genoma: European clinical genetics and genomics laboratory network under Eurofins, providing NIPT, PGT, hereditary cancer and WES—directly comparable to Genoks' clinical genetics portfolio with broader geographic reach.

Regional players

• Medicover Genetics: Europe/MENA diagnostics provider with a dedicated genetics unit offering NIPT, carrier screening, and hereditary panels—a regional peer operating in overlapping European markets and Turkey's neighbouring geographies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genoks